PDS Biotech FY2022 net loss $40.9M; cash to Q3 2024; PDS0101 shows 100% response in cervical cancer

PDS Biotechnology Corp

Net loss for 2022 was $40.9M ($1.43/share) vs $16.9M ($0.66/share) in 2021; R&D expenses rose to $29.4M.
Cash balance of $73.8M as of Dec 31, 2022; management expects funds into Q3 2024.
FDA meeting supported registrational pathway for triple combo (PDS0101, PDS0301, ICI) in HPV+ cancers.
IMMUNOCERV trial: 100% clinical response (9/9 >60% tumor shrinkage) in high-risk cervical cancer patients.
Signed exclusive global license for PDS0301 from Merck KGaA for $10M ($5M cash + $5M in stock).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PDS Biotechnology Corp reported the year ended December 31, 2022 results: net income approximately $40.9 million, EPS $1.43 per basic share and diluted share.

Period: the year ended December 31, 2022
Net income: approximately $40.9 million
EPS: $1.43 per basic share and diluted share
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2022 was approximately $40.9 million, or $1.43 per basic share and diluted share

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-23-014118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.